January 26th, 2023 | 🕒
https://www.ispeech.org/text.to.speech Sabela Ojea Levi Strauss & Co. said Wednesday that it expects revenue and earnings growth in 2023 after beating
January 16th, 2023 | 🕒
https://www.ispeech.orgDefence Therapeutics to get US patent linked to vaccine technology Seeking Alpha Source link
January 10th, 2023 | 🕒
iSpeech TULSA, Okla., Jan. 10, 2023 /PRNewswire/ -- FortySix Venture Capital LLC (46VC) and The University of Tulsa (TU) announced today
December 30th, 2022 | 🕒
Text to Speech Voices A ChargePoint station at the New Carrollton Branch Library in New Carrollton, Md. Tom Williams |
December 27th, 2022 | 🕒
iSpeech.org U.S. stocks traded mixed toward the end of trading, with the Dow Jones trading slightly higher on Tuesday. The
December 8th, 2022 | 🕒
TTS Funding from the Bill & Melinda Gates Foundation will go toward understanding the benefits of novel cap analogs for
December 8th, 2022 | 🕒
iSpeech.org Funding from the Bill & Melinda Gates Foundation will go toward understanding the benefits of novel cap analogs for
December 3rd, 2022 | 🕒
iSpeech Marvell Technology Group Source: marvell.com Check out the companies making headlines before the bell: Marvell Technology (MRVL) – The
November 14th, 2022 | 🕒
iSpeech Patent advances Dewpoint's leadership in the discovery of biomolecular condensate modulators with vast potential to treat diseases New technology
November 1st, 2022 | 🕒
Powered by iSpeech Isle of Man, Nov. 01, 2022 (GLOBE NEWSWIRE) -- We've recently updated our comparison engine to feature
November 1st, 2022 | 🕒
iSpeech Douglas Insights The market for therapeutics for women's health technology is expected to grow by a compound annual growth
October 16th, 2022 | 🕒
https://www.ispeech.org/text.to.speech Credit: Acuitas Therapeutics Getting involved with the Pfizer vaccine was part luck, part timing and part innovation for Madden's
September 13th, 2022 | 🕒
iSpeech.org TEL AVIV, Israel, Sept. 13, 2022 /PRNewswire/ -- Microtech, a wholly owned subsidiary of Medinol, Inc., a leader in
September 6th, 2022 | 🕒
iSpeech.org Synaffix to provide access to proprietary ADC technologies (GlycoConnect™, HydraSpace™ and exatecan-based SYNtecan E™ linker-payload) Emergence Therapeutics secures rights
Gloss